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Abstract
Objective: To obtain whether there was a correlation 
between the Sassone morphological index and CA 125 
tumour markers for suspecting epithelial ovarian cancer 
with serous types.
Methods: This research was analysis correlation and 
diagnostic test using cross-sectional design. This study was 
conducted in Dr. Zainoel Abidin Hospital, from November 
2018 until April 2019.
Results: There were 30 samples of patients with suspected 
malignant ovarian tumours. The Mann-Whitney test has 
been performed and the results show no relationship 
between the Sassone morphological index and epithelial 
ovarian cancer with serous type (p-value 0.627) and there 
was no correlation between CA 125 tumour marker and 
epithelial ovarian cancer with serous types (p-value 0.251). 
The diagnostic test was performed to examine the sensitivity 
and specifi city for the Sassone morphological index in 
epithelial ovarian cancer with serous type, resulting in 60% 
and 28%, respectively. In this study, the sensitivity and 
specifi city for CA 125 tumour marker in epithelial ovarian 
cancer with serous type were 80% and 40%, respectively.
Conclusions: There was no correlation between the 
Sassone morphological index and CA 125 tumour marker 
for suspecting epithelial ovarian cancer with serous types.
Keywords: CA 125 tumour marker, epithelial ovarian cancer 
with serous types, morphological index of Sassone.
Abstrak
Tujuan: Untuk mengetahui adakah korelasi antara indeks 
morfologi Sassone dan penanda tumor CA 125  dalam 
memprediksi kanker ovarium epitelial tipe serous.
Metode: Penelitian ini menggunakan rancangan potong 
lintang dengan melakukan uji  korelasi dan diagnostik.
Penelitian dilakukandi RSUD Dr. Zainoel abidin, dalam kurun 
waktu November 2018 sampai dengan April 2019.
Hasil: Selama penelitian didapatkan 30 sampel penderita 
tumor ovarium suspek ganas. Dilakukan analisis dengan uji 
Mann-Whitney, didapatkan tidak terdapat hubungan antara 
indeks morfologi Sassone terhadap kanker ovarium epitelial 
tipe serous (p-value 0,627) dan tidak terdapat hubungan 
antara penanda tumor CA 125 terhadap kanker ovarium 
epitelial tipe serous (p-value 0,251). Kemudian dilakukan uji 
diagnostik dimana didapatkan nilai sensitivitas, spesifi sitas 
dari indeks morfologi Sassone pada kanker ovarium epitelial 
tipe serous adalah 60% dan 28%. Sedangkan nilai sensitivitas 
dan spesifi sitas penada tumor CA 125 pada kanker ovarium 
epitelial tipe serous pada penelitian ini didapatkan 80% dan 
40%.
Kesimpulan: Tidak ada hubungan antara indeks morfologi 
Sassone dan penanda tumor CA 125 dalam memprediksi 
kanker ovarium epitelial tipe serous.
Kata kunci: indeks morfologi Sassone, kanker ovarium 
epitelial tipe serous,  penanda tumor CA 125.
INTRODUCTION
Ovarian cancer cases tend to increase in 
developing countries with cases of more than 
20% of all genital cancers in women.1,2  In the 
last two decades, cancer cases in these women 
have continued to increase with the most cases 
being epithelial type, while the type of germinal 
is mostly found in women especially in a child or 
adolescent age. In women aged over 45 years will 
increase the risk of getting this cancer.3
Indonesia as a developing country, cases of 
ovarian tumours tend to increase every year. 
Based on national cancer registration data in 
2012 it was found that ovarian cancer was in 
the second rank (23.43%) after cervical cancer 
(63.39%).4 Other data obtained from the Jakarta 
Cancer Registry stated that the incidence rate 
of ovarian cancer is 4.27 cases per 100,000 
population and rank third after breast cancer and 
cervical cancer.5
The biggest challenge of ovarian cancer due to 
the diffi culty of examinations to detect because 
in the early stages there are no symptoms 
and symptoms are found when experiencing 
metastases.6 The life expectancy of the patients 
who suffer from ovarian cancer will be higher 
if ovarian cancer is found as early as possible 
at an early stage, this will impact on decreased 
morbidity and mortality in patients with ovarian 
cancer. Like other cancers, there is an increase in 
populations migrate from low-risk countries to 
higher risk countries, indicating a possible role 
for food and environmental factors.7
CA 125 is a glycoprotein used for screening 
epithelial ovarian cancer. If the CA value is 
more than 35 U / mL, it is likely to suffer from 
epithelial malignant ovarian tumour. But CA 125 
is not specifi cally for malignat ovarian tumour 
with epithelial type and tend to rise on the 
other conditions such as endometriosis, other 
malignancies (breast, lung, colon and endometrial 
cancers), PID and peritonitis.1
It was found that as many as 75 percent of 
cases of serous ovarian epithelial cancer had an 
increase in CA 125 tumour markers with an average 
value of 156 U / ml. 8 Also found 80% of CA 125 
tumour markers rose in these cancer patients, 
with a sensitivity of 50% in the early stages and 
90% and advanced stages. 2 Examination of CA 
125 tumour markers in postmenopausal women 
has a PPV of 98% and NPV of 72%, whereas in 
premenopausal women have a PPV of 49%.9
The value of tumour markers and 
ultrasonography for screening epithelial 
ovarian cancer remain unclear. Transabdominal 
ultrasound screening results increase, but 
specifi city has a limitation.10 Ultrasonography is 
an indicator to predict malignancy that can be 
seen from irregular thickening of the cystic wall 
or septa (> 3 mm), the presence of vegetation 
or papillary features, the presence of greater 
cystic mass of 10 cm, and the presence of solid 
components.11
Ultrasonography is one of the most important 
tools in examining and assessing adnexal 
disorders. Suspicion of malignancy in patients 
with ovarian tumours if fl uid is found in the 
abdominal cavity and nodules in the peritoneum 
on abdominal or vaginal ultrasound examination. 
Doppler ultrasound examination can be used to 
look for neovascular in dense masses and areas 
of cystic mass. In a meta-analysis of 46 studies 
(5,159 patients) a combination of morphology 
and Doppler ultrasound could increase sensitivity 
and specifi city.12
Ultrasonography is a modality examination for 
ovarian tumours to identify the nature of tumours 
before surgery using a morphological assessment 
system, which links morphological images and 
macroscopic pathological characteristics of 
ovarian tumours.13
Table 1. Morphology Index of Sassone14
Inner wall structure
Smooth
Irregularities ≤ 3 mm
Papillarities > 3 mm
Not applicable, 
mostly solid
Wall thickness
Thin, ≤ 3 mm
Thick, > 3 mm
Not applicable, 
usually dense
Septa
None Sonolucent
Not thick, ≤ 3 mm
Thick, > 3 mm
Echogenicity
Sonolucent
Poor echogenicity
Poor echogenicity, with 
echogenic score
Blended echogenicity
Elevated echogenicity
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One of the morphological index assessment 
to determine the nature of ovarian tumours is the 
morphological index of Sassone, with assessing 
the inner wall structure, septa, wall thickness and 
echogenicity of a tumour (Table 1.).14
Limitations of examining tumour marker of 
CA 125 in several peripheral areas in Aceh, the 
authors try to use other tests to fi nd ovarian 
cancer quickly. For this reason, the authors use 
ultrasonography modalities, which can be found 
in peripheral areas in Aceh, by calculating the 
morphological index of Sassone in the study.
The purposed of this research was to fi nd 
out whether there was a correlation between 
the morphological index of Sassone and tumour 
markers of CA 125 in predicting serous type of 
epithelial ovarian cancer. It is expected that the 
results of the study can be used in areas that do 
not have any CA 125 tumour markers, if the study 
found that the morphological index of Sassone 
has a higher sensitivity and specifi city than CA 
125 tumour markers.
METHODS
This research was cross-sectional study by 
conducting analysis correlation and diagnostic 
tests. This study was conducted at Dr. Zainoel 
Abidin Hospital (RSUDZA), from November 2018 
to April 2019. All samples were suspected to be 
malignant ovarian tumours were included in the 
inclusion criteria such as new patients, patients 
had never undergone surgery, patients had never 
undergone neoadjuvant chemotherapy, patients 
who would undergo surgery at RSUDZA, and 
patients with tumour ovary suspected malignant. 
The exclusion criteria were patients with residual 
ovarian cancer, patients who have had surgery 
in other hospitals with open and closed cases, 
and patients with ovarian cancer who were 
metastasized from other places. Then all pastients 
who came to the emergency department/
obstetrics and obstetric diseases were performed 
examination of CA 125 tumour markers of 
morphology index of Sassone in the Radiology 
department, then surgery was performed and the 
results of the surgery were sent to the Pathology 
Anatomical department to confi rm serous type 
of epithelial ovarian cancer.
RESULTS
This study involved 30 samples that suffered 
from the suspected malignant ovarian tumour. 
Based on table 2, there were 5 samples (16.7%) 
with histopathological results of the serous type 
of epithelial ovarian cancer, while the remaining 
83.3% with non-serious type of epithelial ovarian 
cancer. Furthermore, it could be known that 20 
samples (66.7%) with a morphological index of 
Sassone were greater than 9, while the remaining 
33.3% with the morphological index of Sassone 
below 9. Table 2, also showed that 11 samples 
(36.7%) with CA 125 tumour marker value were 
greater than 35, while the remaining of 63.3% 
with CA 125 tumour marker value were under 
35. From 30 research samples were known that 
15 samples (50%) of them were greater than 45 
years old, while the rest of 50% were under 45 
years old.
Based on table 3, it was known that 3 samples 
(10%) with a morphological index of Sassone were 
greater than 9 and had histopathological results 
of serous type of epithelial ovarian cancer, while 
the remaining of 6.7% with morphology index 
of Sassone below 9 and had histopathological 
results of serous type of epithelial ovarian cancer. 
Table 3, also showed that 4 samples (13.3%) with 
CA 125 tumour marker values greater than 35 
were equal and had histopathological results 
serous type of epithelial ovarian cancer, while the 
remaining of 3.3% with CA 125 tumour marker 
values below 35 and had histopathological results 
serous type of epithelial ovarian cancer.
Table 2. Characteristics of the Sample Based on Histopa-
thology, Morphological Index of Sassone, CA 125 Tumour 
Marker and Age Group
Variables Total (samples)
Histopathology
Serous type of epithelial cancer
Non Serous type of epithelial cancer
Morphology index of  Sassone
< 9
≥ 9
Ca 125 U/ml
< 35
≥ 35
Age (y.o)
< 45
≥ 45
5
25
10
20
19
11
15
15
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Table 3. Characteristics of Samples Based on a Morphological 
Index of Sassone and Tumour Marker of Ca 125 with Serous 
Type Epithelial Ovarian Cancer
Table 4. Comparison of the Morphological Index of Sassone and the Values of CA 125 Tumour Marker 
between Epithelial Ovarian Cancer with Serous Type and non Serous Type.
Variable
Variable Avarage SD P-value
Serous type of 
epithelial cancer 
(samples)
Morphological index of Sassone
< 9
≥ 9
Ca 125 U/ml
< 35
≥ 35
Morphological index of Sassone
Non Serous type of epithelial cancer
Serous type of epithelial cancer
CA 125
Non Serous type of epithelial cancer
Serous type of epithelial cancer
10.28
10.60
349.25
165.34
2.11
4.04
1132.86
91.48
0.627a
0.251a
2 
3 
1 
4 
Table 4, showed comparison of the 
morphological index of Sassone and Ca 125 
tumour markers values in the epithelial ovarian 
tumour malignant group with serous type and 
non-serous type, it was showed that the value of 
CA 125 tumour markers in the epithelial ovarian 
Measuring the morphological index of 
Sassone compared to tumour markers of CA 
125 against serous type of epithelial cancer 
were required special examinations such as 
sensitivity and specifi city analysis, positive and 
negative likelihood ratio, positive and negative 
predictive value and accuracy. In the diagnostic 
test, the morphological index of Sassone was 
classifi ed into 2 categories: mild if the results of 
the morphological index of Sassone were below 
9, and suspected malignant if the morphological 
index of Sassone was greater than 9. Tumour 
markers of CA 125 values were categorized as 
mild if CA 125 values below 35 and suspects 
malignant if the CA 125 value was greater than 
35.
Diagnostic test results showed that the use of 
morphological index of Sassone as a predictor 
of serous type epithelial ovarian cancer would 
have sensitivity value of 60%, specifi city value 
of 28%, PPV of 14%, NPV of 78%, positive and 
negative likelihood ratio were 0.83 and 1.42, 
respectively and accuracy were 33.3%. While the 
diagnostic test results of CA 125 tumour marker 
as a predictor serous type of epithelial ovarian 
tumour malignat group with non-serous type 
was much greater than the epithelial ovarian 
cancer group with serous type, but statistically 
the two groups had different CA 125 tumour 
marker values. This was because the CA 125 
tumour marker value in the non serous type of 
epithelial ovarian cancer had a very large SD value. 
Furthermore, the Mann-Whitney test results in 
Table 4, showed that the epithelial ovarian cancer 
with serous type and non serous type also had the 
same morphological index of Sassone statistically 
indicated by the p-value testing greater than 
0.05. Both of these comparison results show 
that the CA 125 tumour marker value and the 
morphological index of Sassone in this study had 
not been able to distinguish between epithelial 
ovarian cancer with serous type and non serous 
type
cancer had sensitivity value of 80%, specifi city 
value of 40%, PPV of 21%, NPV of 91%, positive 
and negative likelihood ratio were 1.33 and 0.50, 
respectively and accuracy was 46.7%.
 
DISCUSSION
The study involved 30 samples obtained from 
primary data collected from November 2018 to 
April 2019. Patient characteristics by age were 
15 samples (50%) of which were older than 45 
years old with 12 samples having malignant 
histopathology. Furthermore, as many as 50% 
under 45 years old in which 4 samples had 
the results of malignant histopathology. This 
is consistent with the literature that the age of 
occurrence of ovarian cancer is most often above 
the 45 years old with the incidence increasing 
signifi cantly at the 45-54 years old.3,15 Even 
though, statistics on ovarian cancer in 2018 
showed a higher incidence in women over 65 
compared to women under 65 years old.16
Based on this research, only 5 samples 
(16.67%) from 30 ovarian cancer patients were 
included in epithelial malignant ovarian tumour 
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with serous type, the remaining 25 samples 
(83.33%) included in epithelial malignant ovarian 
tumour with non-serous type. This differs from 
the literature which found that the incidence 
rate of epithelial malignant ovarian tumour with 
serous type was 60%.17,18 The registration data 
of cancer centres in North America in 2016, the 
classifi cation of ovarian cancer was serous 52%, 
endometrioid 10%, mucinous and clear cells were 
6%.19
The CA 125 tumour marker was the primary 
examination of ovarian cancer and fallopian tube, 
epithelial ovarian cancer when the value is greater 
than 35 U / mL.1,20 Increased concentration tumour 
markers of CA 125 found in 75% of women 
with serous type of epithelial ovarian cancer, 
mentioned that increased concentrations occur 
in women with ovarian serous type of epithelial 
cancer followed by endometrioid and clear cell 
types.8,21,22
It is not suitable with the results of this study 
in which the CA 125 value only increased in 4 
samples (13.3%) with histopathological results 
serous type of epithelial ovarian cancer from a 
total of 30 samples (p-value 0.251). So from the 
study, it was found that there was no correlation 
between increasing the value of CA 125 tumour 
marker and epithelial ovarian cancer with serous 
type.
Characteristics of benign or malignant 
ovaries could be confi rmed by ultrasonography 
as the main imaging modality. The ultrasound 
morphology correlated with the macroscopic 
pathological picture of ovarian mass, with the 
highest scoring score on PID, corpus luteum 
cysts and the lowest score on serous ovarian 
cystadenoma.23 In this study, the ultrasound 
examination used the morphology index of 
Sassone, which assessed the inside of wall 
structure, wall dense, septum and resonance. 
From the assessment conducted only 3 samples 
(10%) with a serous type of epithelial ovarian 
cancer with a morphological index of Sassone 
greater than 9 (p-value 0.623). It can be stated 
that there is no relationship between Sassone 
morphological index and epithelial ovarian 
cancer with serous type.   
In this study, the morphology index of 
Sassone was greater than 9 are 3 samples that 
were diagnosed with a serous type of epithelial 
ovarian cancer, with sensitivity value 60%, 
specifi city 28%, PPV 14%, NPV 78%, positive 
and negative likelihood ratio were 0.83 and 1.42, 
respectively and accuracy was 33 %. With positive 
and negative likelihood ratio values were below 
10 and above 0.1, respectively. These results 
stated that the morphological index of Sassone 
had a poor diagnostic value. This was different 
from the study that had been done by Desai et al, 
who obtained a higher sensitivity value of 81.8% 
and the specifi city value of the index was 92.3% in 
the Sassone morphological index in patients with 
malignant ovarian masses.24 The study that has 
been done, found sensitivity, specifi city values, 
PPV, NPV, and accuracy are 89.5%, 78.4%, 68%, 
93.5% and 82.1%.25 From the study who obtained 
the sensitivity value was 91.7% and the specifi city 
value was 77.7 % in the Sassone morphological 
index  in women with an adnexal mass.26
Mentions that patients with malignant ovarian 
masses of serous type, the sensitivity value of CA 
125 84% compared to mucinous, endometrioid, 
clear cell and undifferentiated types were 66.7%, 
80%, 33.7% and 95%.27 Whereas in the study it 
was found that CA 125 value was greater than 35 
U / mL were 4 samples that were diagnosed with 
serous type of epithelial ovarian cancer, with a 
sensitivity value 80%, specifi city 40%, PPV 21%, 
NPV 91%, positive and negative likelihood ratio 
were 1.33 and 0.50, respectively and accuracy was 
46.7%. With positive and negative likelihood ratio 
values were below 10 and above 0.1, respectively. 
It was indicated that the morphological index of 
Sassone had a poor diagnostic value.
The two statistical studies that previously 
done were comparative analysis of CA 125 
tumour marker values and morphological index 
of Sassone between serous type and non-serous 
of epithelial ovarian malignant tumour, and 
diagnostic test such as sensitivity and specifi city, 
PPV, NPV, positive and negative likelihood ratio 
and accuracy indicate that CA 125 values and 
the morphological index of Sassone in the study 
could not be used as good predictors of serous 
type of epithelial ovarian cancer. It also could be 
concluded that the use of the morphological index 
of Sassone had not been proven to be statistically 
better than the tumour marker of CA 125 as a 
predictor of serous type epithelial ovarian cancer. 
The results of the two tests showed that the use 
of curves of the receiver operating characteristic 
to determine the cut-off point of each CA 125 
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predictor variable and the morphological index 
of Sassone for the serous type of epithelial 
ovarian cancer could not be performed because 
it would give biased results. One reason why the 
results were not good was that the number of the 
samples from serous type of epithelial ovarian 
cancer was very small. Increasing the number of 
the sample from epithelial ovarian cancer with 
serous type will make the result better.
CONCLUSION
There was no correlation between the 
morphological index of Sassone and epithelial 
ovarian cancer with serous type, p-value 0.627. 
The CA 125 tumour markers were not related 
to the epithelial ovarian malignat tumour with 
serous type, p-value 0.251. 
SUGGESTION
For further study, we need a larger sample to 
suspect a serous type of epithelial ovarian cancer 
for diagnostic the disease quickly and accurately.
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